Trial Profile
A Phase 1, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effect of the Modulators of the Cytochrome P450 (CYP) 2C8 and/or 3A on the Single-Dose Pharmacokinetics of Ozanimod and CC112273 in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary) ; Gemfibrozil; Itraconazole; Rifampicin
- Indications Crohn's disease; Multiple sclerosis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 28 Aug 2020 Results published in the Advances in Therapy
- 28 May 2019 Status changed from recruiting to completed.
- 20 Aug 2018 New trial record